Oxcarbazepine
Oxtellar, Trileptal (oxcarbazepine) is a small molecule pharmaceutical. Oxcarbazepine was first approved as Trileptal on 2000-01-14. It is used to treat epilepsy and partial epilepsies in the USA.
Download report
Favorite
Novartis Pharmaceuticals
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
Oxtellar, Trileptal (generic drugs available since 2007-10-09)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| oxcarbazepine | ANDA | 2023-06-16 |
| oxtellar xr | New Drug Application | 2020-12-23 |
| trileptal | New Drug Application | 2021-06-03 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| epilepsy | EFO_0000474 | D004827 | G40.9 |
| partial epilepsies | EFO_0004263 | D004828 | — |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
49 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 4 | — | 2 | 3 | 5 | 14 |
| Partial epilepsies | D004828 | EFO_0004263 | 2 | — | 5 | 1 | — | 8 | |
| Seizures | D012640 | G40.4 | 2 | — | — | 1 | 3 | 6 | |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | 4 | 1 | 5 |
| Trigeminal neuralgia | D014277 | EFO_1001219 | G50.0 | — | — | — | 2 | — | 2 |
| Metabolic clearance rate | D008657 | — | — | — | 1 | — | 1 | ||
| Conduct disorder | D019955 | EFO_0004216 | F91 | — | — | — | 1 | — | 1 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | — | 1 | — | 1 | |
| Neuralgia | D009437 | EFO_0009430 | — | — | — | 1 | — | 1 | |
| Postherpetic neuralgia | D051474 | — | — | — | 1 | — | 1 |
Show 5 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | OXCARBAZEPINE |
| INN | oxcarbazepine |
| Description | Oxcarbazepine is a dibenzoazepine derivative, having a carbamoyl group at the ring nitrogen, substituted with an oxo group at C-4 of the azepeine ring which is also hydrogenated at C-4 and C-5. It is a anticholinergic anticonvulsant and mood stabilizing drug, used primarily in the treatment of epilepsy. It has a role as an anticonvulsant and a drug allergen. It is a dibenzoazepine and a cyclic ketone. It contains a carbamoyl group. |
| Classification | Small molecule |
| Drug class | tricyclic compounds |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | NC(=O)N1c2ccccc2CC(=O)c2ccccc21 |
Identifiers
| PDB | — |
| CAS-ID | 28721-07-5 |
| RxCUI | 32624 |
| ChEMBL ID | CHEMBL1068 |
| ChEBI ID | 7824 |
| PubChem CID | 34312 |
| DrugBank | DB00776 |
| UNII ID | VZI5B1W380 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Oxtellar - Supernus Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,591 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
21 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more